Zydus Gets Tentative USFDA Nod for Deferasirox Tab | CORPORATE ETHOS

Zydus Gets Tentative USFDA Nod for Deferasirox Tab

By: | November 20, 2018

Nov 20: Pharma major Zydus Cadila on Tuesday said that it has received the tentative approval from the USFDA to market its Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (US RLD —
Exjade Tablets).

According to the company, the product is used to treat ongoing high levels ofiron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non—transfusion—dependent thalassemia).

The product will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmadabad, the company added.

The group now has 231 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003—04.